CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 2 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $2,000 | -89.5% | 28,540 | -43.4% | 0.00% | – |
| Q3 2018 | $19,000 | -13.6% | 50,415 | 0.0% | 0.00% | – |
| Q2 2018 | $22,000 | -83.7% | 50,415 | -12.3% | 0.00% | -100.0% |
| Q1 2018 | $135,000 | -77.0% | 57,515 | -72.3% | 0.00% | -80.0% |
| Q4 2017 | $588,000 | -10.8% | 207,515 | -10.1% | 0.01% | -16.7% |
| Q3 2017 | $659,000 | +16.0% | 230,715 | -0.0% | 0.01% | +20.0% |
| Q2 2017 | $568,000 | -33.8% | 230,780 | -4.1% | 0.01% | -37.5% |
| Q1 2017 | $858,000 | -1.3% | 240,680 | -2.9% | 0.01% | -11.1% |
| Q4 2016 | $869,000 | -9.4% | 247,870 | +4.1% | 0.01% | -18.2% |
| Q3 2016 | $959,000 | -9.9% | 238,095 | -2.6% | 0.01% | -15.4% |
| Q2 2016 | $1,064,000 | +13.2% | 244,345 | -1.3% | 0.01% | +333.3% |
| Q1 2016 | $940,000 | +33.5% | 247,570 | +456.7% | 0.00% | -62.5% |
| Q4 2015 | $704,000 | +46.7% | 44,470 | -1.8% | 0.01% | +33.3% |
| Q3 2015 | $480,000 | – | 45,274 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 844,981 | $15,421,000 | 7.11% |
| DOHENY ASSET MANAGEMENT /CA | 195,345 | $3,565,000 | 1.70% |
| First Light Asset Management, LLC | 153,617 | $2,804,000 | 1.59% |
| Rhenman & Partners Asset Management AB | 175,000 | $3,194,000 | 0.93% |
| Iguana Healthcare Management, LLC | 100,000 | $1,825,000 | 0.88% |
| Eventide Asset Management | 288,700 | $5,269,000 | 0.58% |
| Bedell Frazier Investment Counselling, LLC | 60,820 | $1,110,000 | 0.54% |
| STONERIDGE INVESTMENT PARTNERS LLC | 214,327 | $3,911,000 | 0.52% |
| Fernwood Investment Management, LLC | 31,350 | $572,000 | 0.49% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 168,560 | $3,076,000 | 0.37% |